| Daniel J Kohane, MD | |
|
500 W Main St, Suite 116, Babylon, NY 11702-3027 | |
| (631) 422-6166 | |
| (631) 422-6266 |
| Full Name | Daniel J Kohane |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 18 Years |
| Location | 500 W Main St, Babylon, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235399734 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ns/lij Hs Southside Hospital | Bay shore, NY | Hospital |
| North Shore University Hospital | Manhasset, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York Pain Consultants Llc | 0749260107 | 18 |
News Archive
Marked for death with molecular tags that act like a homing signal for a cell's protein-destroying machinery, a pivotal enzyme is rescued by another molecule that sweeps the telltale targets off in the nick of time.
EntreMed, Inc., today announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma cell lines and in MM models in vivo. Results of the study, conducted by EntreMed's collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana University School of Medicine, were published in the on-line version of the British Journal of Haematology on June 15, 2010 and are scheduled to be published in print in the August 1, 2010 issue.
New genetic evidence strengthens the case that one well-known type of cholesterol is a likely suspect in causing heart disease, but also casts further doubt on the causal role played by another type.
More than half of working-class whites say [the federal health law] is a bad idea. Perhaps most stunningly, so do 48% of those currently without health insurance-;the very people who stand to gain the most, in the form of help finding and paying for coverage. Meanwhile, by a 30-point margin, political independents think they will be worse off under the law.
› Verified 3 days ago
| Entity Name | New York Pain Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639190630 PECOS PAC ID: 0749260107 Enrollment ID: O20040726000061 |
News Archive
Marked for death with molecular tags that act like a homing signal for a cell's protein-destroying machinery, a pivotal enzyme is rescued by another molecule that sweeps the telltale targets off in the nick of time.
EntreMed, Inc., today announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma cell lines and in MM models in vivo. Results of the study, conducted by EntreMed's collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana University School of Medicine, were published in the on-line version of the British Journal of Haematology on June 15, 2010 and are scheduled to be published in print in the August 1, 2010 issue.
New genetic evidence strengthens the case that one well-known type of cholesterol is a likely suspect in causing heart disease, but also casts further doubt on the causal role played by another type.
More than half of working-class whites say [the federal health law] is a bad idea. Perhaps most stunningly, so do 48% of those currently without health insurance-;the very people who stand to gain the most, in the form of help finding and paying for coverage. Meanwhile, by a 30-point margin, political independents think they will be worse off under the law.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel J Kohane, MD 11350 Mccormick Rd, Executive Plaza 1, Ste. 501, Hunt Valley, MD 21031 Ph: (703) 914-8000 | Daniel J Kohane, MD 500 W Main St, Suite 116, Babylon, NY 11702-3027 Ph: (631) 422-6166 |
News Archive
Marked for death with molecular tags that act like a homing signal for a cell's protein-destroying machinery, a pivotal enzyme is rescued by another molecule that sweeps the telltale targets off in the nick of time.
EntreMed, Inc., today announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma cell lines and in MM models in vivo. Results of the study, conducted by EntreMed's collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana University School of Medicine, were published in the on-line version of the British Journal of Haematology on June 15, 2010 and are scheduled to be published in print in the August 1, 2010 issue.
New genetic evidence strengthens the case that one well-known type of cholesterol is a likely suspect in causing heart disease, but also casts further doubt on the causal role played by another type.
More than half of working-class whites say [the federal health law] is a bad idea. Perhaps most stunningly, so do 48% of those currently without health insurance-;the very people who stand to gain the most, in the form of help finding and paying for coverage. Meanwhile, by a 30-point margin, political independents think they will be worse off under the law.
› Verified 3 days ago
Dr. Luis M Fandos, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 W Main St, Suite 116, Babylon, NY 11702 Phone: 631-422-6166 Fax: 631-422-6266 |